Novo Nordisk A/S
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Stephan Engels | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 312.50 | 6,450 | |||||
| d) | Aggregated information
| 6,450 shares DKK 2,015,625.00 | ||||
| e) | Date of the transaction | 2025-11-17 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Max Ung +45 3077 6414 mxun@novonordisk.com | Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
| Alex Bruce +45 34 44 26 13 axeu@novonordisk.com | Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 36 / 2025
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Meltwater17.11.2025 19:10:43 CET | Press release
Meltwater Named a Leader in IDC MarketScape: Worldwide Influencer Marketing Platforms for Large Enterprises 2025-2026 Vendor Assessment
German High Street Properties A/S17.11.2025 18:40:00 CET | Press release
Financial calendar 2025 and 2026
Harvia Oyj17.11.2025 18:00:00 CET | Press release
Harvia’s Chair of the Board of Directors changes: Catharina Stackelberg-Hammarén elected as the new Chair
Verkkokauppa.com Oyj17.11.2025 18:00:00 CET | Press release
Verkkokauppa.com Oyj: Acquisition of own shares on 17 November 2025
Syensqo SA17.11.2025 17:45:00 CET | Press release
Syensqo - Acquisition of own shares
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom